Skip to main content
Maria Arcila, MD, Pathology, New York, NY

MariaE.ArcilaMD

Pathology New York, NY

Hematopathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology

Lab Director, Diagnostic Molecular Pathology. Deputy Chief, Molecular Diagnostics Service. Medical Director, Molecular Hematopathology Memorial Sloan Kettering Cancer Center

Dr. Arcila is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Arcila's full profile

Already have an account?

  • Office

    1275 York Ave
    New York, NY 10065
    Phone+1 212-639-2000

Clinical Expertise

  • Molecular genetic pathology, Hematopathology, Molecular genetics, Molecular Diagnostics

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematopathology, 2009 - 2010
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Molecular Genetic Pathology, 2008 - 2009
  • Madigan Army Medical Center
    Madigan Army Medical CenterResidency, Pathology-Anatomic and Clinical, 2000 - 2003
  • Tripler Army Medical Center
    Tripler Army Medical CenterInternship, Surgery, 1997 - 1998
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1997

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2007 - 2026
  • NJ State Medical License
    NJ State Medical License 2022 - 2025
  • VA State Medical License
    VA State Medical License 1999 - 2010
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Pathology - Molecular Genetic
  • American Board of Pathology Hematopathology

Awards, Honors, & Recognition

  • Highly Cited Researcher Clarivate, 2019-2023

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a ...  
    Maria E.Arcila MD, Soo-Ryum Yhan BS, Daniela Elezovic BS, Ryma Benayed PhD, Ahmet Zehir PhD, Darren J. Buonocang, MDAmirMomeni MD, Douglas A. Mata MD, Paulo Salazar BS..., JTO Clinical and Research Reports Volume 1, Issue 3, September 2020, 100077, 9/2020
  • Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
    Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature

Books/Book Chapters

Abstracts/Posters

  • Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis
    Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase
    Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
    Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Molecular Diagnostics of Lymphoma: Classification, risk assessment and monitoring 
    USCAP course - A Primer in Precision Pathology: Genomics, Al and Immuno-Oncology - 3/21/2022
  • IASLC Hot Topics 2020: Liquid biopsy 
    Worldwide Virtual Event - 10/2/2020
  • Virtual Tumor Board®: Global Perspectives on Comprehensive NGS Profiling to Personalize Treatment in Cancer 
    8/14/2020
  • Join now to see all

Authored Content

  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase InhibitorsJanuary 2018

Press Mentions

  • Dissolving Knowledge Gaps Regarding EGFR Exon 20 Insertion-Mutant NSCLC
    Dissolving Knowledge Gaps Regarding EGFR Exon 20 Insertion-Mutant NSCLCJuly 6th, 2022
  • MSK’s Research Roundup at AACR 2022: Targeted Therapy for Lung Cancer, Using Statins with a Breast Cancer Drug, and Diagnosing Blood Cancer
    MSK’s Research Roundup at AACR 2022: Targeted Therapy for Lung Cancer, Using Statins with a Breast Cancer Drug, and Diagnosing Blood CancerApril 11th, 2022
  • Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
    Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTSSeptember 6th, 2018
  • Join now to see all